PRAX Earnings Prediction
The chart below shows how PRAX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PRAX sees a -2.06% change in stock price 10 days leading up to the earnings, and a +4.40% change 10 days following the report. On the earnings day itself, the stock moves by +0.18%. This data can give you a slight idea of what to expect for the next quarter's release.
PRAX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
302.00K
-35.47%
-15.41%
Gross Margin
--
--
--
Operating Margin
-18819.54%
245.18%
79.22%
Net Margin
-17188.74%
226.58%
87.79%
EPS
-2.75
-1.10%
58.05%
No Data Available
PRAX Earnings Analysis
Praxis Precision Medicines, Inc. Common Stock Corporation (PRAX.O) Earnings Conference Call
Positive
Phase 3 Study Progress: The Phase 3 study in Essential Tremor continues to progress well, with all aspects of the interim analysis confirmed and plans to have results in Q1 2025.
Clinical Trial Progress: The Phase 2 RADIANT and Phase 2/3 POWER1 trials are on track for top-line results next year, indicating strong potential for future growth.
R&D Expense Allocation: In Q3, the company reported operating expenses of $57.1 million, with $41.9 million allocated for R&D, reflecting increased clinical activity in their movement disorder and epilepsy programs.
Cash Position Increase: Praxis ended Q3 with $411.2 million in cash, compared to $81.3 million at December 31, 2023, primarily due to net proceeds from public offerings earlier this year.
EMPower Study Patient Engagement: The innovative EMPower study launched in Q3 attracted the interest of over 1,000 patients registered in the study, highlighting significant unmet needs for millions of patients with Essential Tremor.
Negative
Operating Expenses Overview: In Q3, our operating expenses were $57.1 million, with $41.9 million of that for R&D, reflecting an increase in clinical activity in our movement disorder and epilepsy programs.
Operating Cash Expenditure: During the third quarter, Praxis spent $27.7 million in operating cash, similar to the second quarter of 2024, reflecting our focus on working capital.
Cash Position Improvement: We ended Q3 with $411.2 million in cash, compared to $81.3 million of cash at December 31, 2023, with the increase primarily due to the net proceeds from Praxis follow-on public offerings earlier this year.
Cash Runway Support: Our cash supports the runway into 2027 and includes funding all of the programs that Marc discussed today through their readouts.
Sodium Channel Modulators Progress: We are very excited about both the potential and the progress of our sodium channel modulators vorinostat and relutrigine and there's a lot more to come in 2025.
PRAX FAQs
How does PRAX typically perform around its earnings report dates?
Is Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PRAX Earning Call Sentiment
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PRAX.O
-6.61%Positive
The earnings call highlights a strong cash position and funding runway, but lacks immediate catalysts like new partnerships or record revenues. While there are clinical advancements, regulatory and clinical trial risks could offset potential gains. The Q&A reveals some uncertainties, such as interim analysis timing and patient enrollment updates, which may concern investors. Given these factors, the stock is likely to remain stable in the short term.
